Covid-19 vaccine: The world’s largest Covid 19 Vaccination Drive has started in India from January 16. So far more than 1 crore healthcare and frontline workers have been vaccinated. At such a time, the speed of vaccination can be further accelerated, if the use of another vaccine is approved. According to a report by the Indian Express, Dr. Reddy Laboratories has sought approval from the Drug Controller General of India (DGCI) for the emergency use of Sputnik-V, a corona vaccine from Russia. At present, the vaccination program is being carried out in the country through two Corona vaccines Covishield and Covaxin.
The third stage trial of Sputnik-V is still pending. It is important to note, however, that before this, DDCI had approved the indigenous vaccine Kovaxine manufactured by Hyderabad-based Bharat Biotech for emergency use without the consequences of Phase III human trials. Currently, doses of covaxin are also being applied in the ongoing vaccination in India.
Also read- Onion became expensive by Rs 14 in one month, expect relief next month
The third phase of the trial is likely to begin on February 21
Russia’s Gameleya National Research Institute of Epidemiology and Microbiology has developed a vaccine against the coronavirus named after the first Soviet satellite. Sputnik V is among the first vaccines to be approved for emergency use in Eurasian countries against the Coronavirus. Dr. Reddy, along with the authorities of Russia, is testing this vaccine on more than 1500 people in the country. According to the report of the Indian Express, the third phase of the trial is likely to start from February 21.
Sputnik V more effective than covishield and covaxin
The Russian vaccine is more effective than covishield and covaxin in fighting the coronavirus. According to the interim results published in the scientific journal Lascent, Sputnik V is 91.6 percent effective, which is much higher than the other two vaccines. CoveShield is 53-79 percent effective, while how effective covaxin is, information is not available.